DK1503746T3 - Farmaceutisk anvendelse af COX-2-inhibitorer i angiogenesefremkaldte öjensygdomme - Google Patents

Farmaceutisk anvendelse af COX-2-inhibitorer i angiogenesefremkaldte öjensygdomme

Info

Publication number
DK1503746T3
DK1503746T3 DK03731699T DK03731699T DK1503746T3 DK 1503746 T3 DK1503746 T3 DK 1503746T3 DK 03731699 T DK03731699 T DK 03731699T DK 03731699 T DK03731699 T DK 03731699T DK 1503746 T3 DK1503746 T3 DK 1503746T3
Authority
DK
Denmark
Prior art keywords
cox
angiogenesis
inhibitors
pharmaceutical use
eye diseases
Prior art date
Application number
DK03731699T
Other languages
English (en)
Inventor
Romulus Kimbro Brazzell
George N Lambrou
Elisabeth Latour
Anna Ottlecz
Jeanette Marjorie Wood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1503746T3 publication Critical patent/DK1503746T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK03731699T 2002-01-23 2003-01-22 Farmaceutisk anvendelse af COX-2-inhibitorer i angiogenesefremkaldte öjensygdomme DK1503746T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0201520.4A GB0201520D0 (en) 2002-01-23 2002-01-23 Pharmaceutical uses
PCT/EP2003/000612 WO2003061645A1 (en) 2002-01-23 2003-01-22 Pharmaceutical use of cox-2 inhibitors in angiogenesis-mediated ocular disorders

Publications (1)

Publication Number Publication Date
DK1503746T3 true DK1503746T3 (da) 2008-02-04

Family

ID=9929598

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03731699T DK1503746T3 (da) 2002-01-23 2003-01-22 Farmaceutisk anvendelse af COX-2-inhibitorer i angiogenesefremkaldte öjensygdomme

Country Status (17)

Country Link
US (3) US20050043410A1 (da)
EP (1) EP1503746B1 (da)
JP (1) JP2005515241A (da)
CN (1) CN1283240C (da)
AR (1) AR038198A1 (da)
AT (1) ATE375154T1 (da)
BR (1) BR0307013A (da)
CA (1) CA2468811C (da)
CY (1) CY1106994T1 (da)
DE (1) DE60316792T2 (da)
DK (1) DK1503746T3 (da)
ES (1) ES2291641T3 (da)
GB (1) GB0201520D0 (da)
MY (1) MY145266A (da)
PT (1) PT1503746E (da)
TW (1) TWI280878B (da)
WO (1) WO2003061645A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
WO2005049014A1 (en) * 2003-11-18 2005-06-02 Pharmacia Corporation Cox-2 inhibitors for the treatment or prevention of diabetes-related ocular disorders
AU2009291747B2 (en) * 2008-09-10 2016-05-26 Genentech, Inc. Methods for inhibiting ocular angiogenesis
US9063000B2 (en) * 2009-05-15 2015-06-23 Glaxosmithkline Llc Using thermal imaging for control of a manufacturing process
US11260048B2 (en) 2017-10-03 2022-03-01 The Schepens Eye Research Institute, Inc. Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
CN114652826B (zh) * 2022-01-24 2022-10-14 景泽生物医药(合肥)有限公司 抗egfr抗体的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652762A (en) * 1970-04-14 1972-03-28 Ciba Geigy Corp Pharmaceutical compositions and methods employing substituted derivatives of 2-anilinophenylacetic acids and esters
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
HRP20010582A2 (en) * 1999-12-08 2002-08-31 Pharmacia Corp Valdecoxib compositions
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
PE20030323A1 (es) * 2001-08-31 2003-05-12 Novartis Ag Composicion farmaceutica
AU2003207453A1 (en) * 2002-01-07 2003-07-24 Pharmacia Corp Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin

Also Published As

Publication number Publication date
US20090247638A1 (en) 2009-10-01
EP1503746B1 (en) 2007-10-10
CY1106994T1 (el) 2012-09-26
CN1283240C (zh) 2006-11-08
ES2291641T3 (es) 2008-03-01
TWI280878B (en) 2007-05-11
CN1620288A (zh) 2005-05-25
JP2005515241A (ja) 2005-05-26
WO2003061645A1 (en) 2003-07-31
AR038198A1 (es) 2005-01-05
DE60316792D1 (de) 2007-11-22
CA2468811C (en) 2011-08-09
GB0201520D0 (en) 2002-03-13
ATE375154T1 (de) 2007-10-15
US20120322874A1 (en) 2012-12-20
DE60316792T2 (de) 2008-07-24
MY145266A (en) 2012-01-13
BR0307013A (pt) 2004-11-03
EP1503746A1 (en) 2005-02-09
US20050043410A1 (en) 2005-02-24
CA2468811A1 (en) 2003-07-31
PT1503746E (pt) 2008-01-10
TW200302081A (en) 2003-08-01

Similar Documents

Publication Publication Date Title
CY2016035I1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
MA29067B1 (fr) Protéines de fusion de RAGE et méthodes d'utilisation
LTPA2017004I1 (lt) Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės-delta inhibitoriai
IS7623A (is) Sískammtalausnar töflusamsetning úr pramipexóli
PL373333A1 (pl) Stosowanie przeciwciał skierowanych przeciw TNFalfa i innego leku
DK1620429T3 (da) Nye heterocykliske forbindelser anvendelige til behandling af inflammatoriske og allergiske sygdomme, fremgangsmåder til deres fremstilling og farmaceutiske sammensætninger indeholdende disse
PL374832A1 (pl) Nowe podstawione benzoimidazolowe postacie dawkowe i sposoby ich stosowania
EP1581622A4 (en) REMODELING AND GLYCOKON JUGATION OF ERYTHROPOETIN
MA28802B1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
IS8597A (is) Samsetningar rísedrónats og aðferðir við notkun þess
EP1855833A4 (en) PLASMATA AND METHOD OF USE THEREOF
CY2017048I1 (el) Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
NO20055211D0 (no) Anti-fungale forbindelser og fremgangsmater for anvendelse
EP1722797A4 (en) ISOCHINOLINE DERIVATIVES AND METHOD FOR THE APPLICATION THEREOF
DK1537096T3 (da) Derivater af dioxan-2-alkylcarbamater, fremstilling og terapeutisk anvendelse heraf
DK1487828T3 (da) Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme
DK1411926T3 (da) Integrininhibitorer til behandling af öjensygdomme
DK1410793T3 (da) Administreringsform af ibuprofen-natrium
DK1667693T3 (da) Præparater og fremgangsmåder til anvendelse af lamellare bodies til terapeutiske formål
NO20050689L (no) Terapeutisk anvendelse
DK1496918T3 (da) Anvendelse af natriummetaarsenit til behandling af tumorer
DE60316792D1 (de) Pharmazeutische verwendung von cox-2-hemmern in angiogenese-vermittelten augenerkrankungen
DK1515959T3 (da) Farmaceutiske salte af reboxetin
EP1978999A4 (en) ISOLATED MCPIP AND APPLICATION METHOD